DriverMap™ Targeted RNA Expression Profiling
DriverMap is a comprehensive product and service portfolio for identifying differential gene expression for biomarker discovery, validating RNA-Seq results, and profiling immunotherapy targets.
CloneTracker™ Barcode Products
Incorporate stable, heritable, and sequenceable barcodes in individual cells or a cell population for clonal cell tracking.
Pooled Lentiviral shRNA and CRISPR Libraries
Cellecta has created one of the most effective and published pooled shRNA library platforms available. We also offer pooled pre-made and custom CRISPR KO, CRISPRa, and CRISPRi libraries, as well as individual constructs.
Complete Loss-of-Function and Gain-of-Function CRISPR Screening Services
We’ll perform any or all steps, from RNAi and CRISPR screening to NGS to data analysis. Cellecta specializes in negative screens (i.e. viability or drop-out) to identify cancer drug targets.
Functional RNAi and CRISPR Screening, Barcoding and Drug Target & Biomarker Discovery
Cellecta Inc., a functional genomics solutions provider, focuses primarily on developing and implementing flexible and scalable broad-based screening and analysis approaches for drug target and biomarker discovery. Our high-throughput functional genetic screening portfolio includes:
- shRNA and CRISPR screening services
- custom and off-the-shelf constructs and pooled libraries
- knockout and knockdown cell lines
that facilitate genome-wide functional screening and the identification and validation of genes involved in critical biological and disease pathways.
Our CloneTracker™ Barcode products enable tracking of cell populations and progeny with stable, genomically integrated, single, identifiable, sequenceable barcodes.
With DriverMap™ Targeted RNA Expression Profiling Service, Cellecta offers a quantitative, multiplexed approach that allows simultaneous profiling of all human protein-coding genes in one reaction, thereby providing a reliable, accurate transcriptome profile with ultra-high sensitivity.
Learn more about Cellecta >
What's New?
NEW Blog Post: Core Population of Cancer Stem Cells Mediates Therapeutic Resistance in Tumors
Blog Post: DriverMap™ Targeted RNA Sequencing of Blood Finds Gene Signatures Linked to Labor
Cellecta Launches five DriverMap™ Predesigned RNA-Seq Panels and Analysis Software
Cellecta, Inc. Signs License Agreement on CRISPR/Cas9 Genome Editing Patents for Tools and Services
